OpGen (OPGN) Reports Q2 Loss of $0.84/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
OpGen Reports Second Quarter Financial Results and Provides Business Update
August 13, 2015 4:02 PM EDTGAITHERSBURG, Md., Aug. 13, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN), an early commercial-stage molecular testing and bioinformatics company, today reported financial results for the three and six months ended June 30, 2015. Highlights of the second quarter of 2015 and recent weeks include:
Acquisition of AdvanDx, Inc., a market leader in rapid molecular testing for microorganism identification Completion of a $6 million financing with Merck Global Health Innovation Fund, LLC (Merck GHI) Expansion and renewal of a... More